Compare GLPG & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GLPG | PHVS |
|---|---|---|
| Founded | 1999 | 2015 |
| Country | Belgium | Switzerland |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 1.7B |
| IPO Year | 2005 | 2021 |
| Metric | GLPG | PHVS |
|---|---|---|
| Price | $32.32 | $25.89 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 4 | 9 |
| Target Price | $31.33 | ★ $39.44 |
| AVG Volume (30 Days) | 86.3K | ★ 532.0K |
| Earning Date | 11-05-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $336,643,201.00 | N/A |
| Revenue This Year | $3.61 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 10.31 | N/A |
| 52 Week Low | $22.36 | $11.51 |
| 52 Week High | $37.78 | $29.80 |
| Indicator | GLPG | PHVS |
|---|---|---|
| Relative Strength Index (RSI) | 56.94 | 54.34 |
| Support Level | $30.73 | $23.79 |
| Resistance Level | $32.75 | $25.44 |
| Average True Range (ATR) | 0.60 | 1.91 |
| MACD | 0.07 | -0.17 |
| Stochastic Oscillator | 78.52 | 41.22 |
Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.